Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This trial is a Phase I study to be conducted in patients with non-MSI-high
advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC) and is
divided in two Parts.
- Dose escalation Part :To determine the Maximum Tolerated Dose (MTD) and the Recommended
Dose for Phase 2 (RP2D) of Debio1143 when combined with a fixed dose of Pembrolizumab.
- Extension Part: To evaluate preliminary efficacy data of the proposed combination.
Phase:
Phase 1
Details
Lead Sponsor:
Centre Leon Berard
Collaborators:
Debiopharm International SA Merck Sharp & Dohme Corp.